To investigate if ST6GAL1 can regulate immunosuppressive sialoglycans in prostate cancer cells, we utilised recently developed Siglec-Fc proteins51 to monitor Siglec ligands in CWR22RV1 prostate cancer cells with upregulation of ST6GAL1, and LNCaP cells with downregulation of ST6GAL1. This evidence concerns the gene ST6GAL1 and prostate carcinoma.